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Population-based identity by descent (IBD) mapping is a statistical method for detection of genetic loci that share
an ancestral segment among “unrelated” pairs of individuals for a disease. As a complementary method to
genome-wide association studies, IBD mapping is robust to allelic heterogeneity and may identify rare inherited
variants when combined with sequence data.
Our objective is to identify the causal genes for diastolic blood pressure (DBP). We applied a population-based IBD
mapping method to 105 unrelated individuals selected from the family data provided for the Genetic Analysis
Workshop 19. Using the genome-wide association study data (ie, the microarray data), chromosome 3 was scanned
for IBD sharing segments among all pairs of these individuals. At the chromosomal region with the most significant
relationship between IBD sharing and DBP, the whole genome sequence data were examined to identify the risk
variants for DBP.
The most significant chromosomal region that was identified to have a relationship between the IBD sharing and
DBP was at 3q12.3 (p = 0.0016), although it did not achieve the chromosome-wide significance level (p = 0.00012).
This chromosomal region contains 1 gene, ZPLD1, which has been reported to be associated with cerebral
cavernous malformations, a disease with enlarged small blood vessels (capillaries) in the brain. Although 24
deleterious variants were identified at this region, no significant association was found between these variants and
DBP (p = 0.40).
We presented a mapping strategy which combined a population-based IBD mapping method with sequence data
analyses. One gene was located at a chromosomal region identified by this method for DBP. However, further study
with a large sample size is needed to assess this result.Background
As more sequence data become available, one of the
challenges is how to identify the disease-causing variants
among hundreds of deleterious variants an individual
carries [1]. Various research strategies, such as the
combined homozygosity mapping and sequence data
analysis approach, have been successfully applied [2].* Correspondence: liu@umanitoba.ca
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Traditional identity-by-descent (IBD) mapping methods
have been successfully applied in studies of Mendelian and
complex diseases using related cases [3]. With the availabil-
ity of high-density genetic markers, such as those from
genome-wide association and next-generation sequencing
studies, it is possible to estimate IBD sharing accurately
between 2 randomly chosen individuals in an outbred
population for relatively short chromosomal regions, for
example, 0.03 to 1 cM instead of 10 to 20 cM from family-
based linkage studies [4–7]. In addition, compared tole is distributed under the terms of the Creative Commons Attribution 4.0
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are more robust to allelic heterogeneity, which has been
observed in complex diseases and traits [8].
To date, a few groups have applied IBD mapping
methods as a complementary method to genome-wide
association studies for complex diseases in large, unrelated
samples [5, 9–11]. For each of these studies, the whole
genome was scanned in order to compare IBD sharing of
each segment in apparently unrelated case-case pairs to
that in case-control and control-control pairs. If there were
rare causative variants at a locus, the case-case pairs would
be expected to share significantly more at this locus than
both the case-control and control-control pairs. Several of
the studies found genome-wide significant excess IBD
sharing for their disease of interest. In contrast, they did
not find any chromosomal regions that reached the level of
genome-wide significance with genome-wide association
methods using the same data.
The population-based IBD mapping methods may also
be applied to quantitative traits [12]. In this study, we
test the hypothesis that diastolic blood pressure (DBP)
levels are related to rare inherited genetic variants that
can be identified using the combined IBD mapping and
sequence data analysis approach.
Methods
Data description
The genome-wide association study (GWAS) data from
the families, which had 959 individuals and 472,049 genetic
markers, were used for quality control procedures, includ-
ing relationship and population structure analyses. Unre-
lated individuals and markers from chromosome 3 of the
GWAS data were used for IBD mapping. Chromosome 3
was chosen according to the suggestions from the Genetic
Analysis Workshop 19 (GAW19) data contributors.
The DBP from the first time point was used as the
outcome. For the individuals with medical treatment for
hypertension, 5 mmHg was added to the original DBP
values [13]. Multiple linear regression was performed with
gender, age, smoking status, and ethnicity (the significant
principal components retrieved using the Eigensoft
program; see “Quality Control” below) as covariates and
the DBP residuals were derived and used to test the rela-
tionship between IBD sharing and DBP.
Quality control
For the GWAS data, individuals were excluded if they had
a genotype missing rate of 5 % or greater or a Mendelian
error rate of 1 % or greater, and markers were excluded if
they were insertion/deletion, had no unique physical
location, a missing rate of 5 % or greater, a Mendelian
error rate of 1 % or greater, a minor allele frequency
(MAF) of 1 % or less, a MAF of 5 % or less with a missing
rate of 1 % or greater, or a Hardy-Weinberg equilibrium(HWE) p value of less than 0.0001. The markers were
further pruned (with r2 < 0.33) for relationship and popu-
lation structure analyses. These quality control procedures
were performed using PLINK v1.07 [4].
The PLINK “–genome” results were used to select unre-
lated individuals. Because Mexican Americans have an-
cestors with different ethnic backgrounds and because the
genetic variants related to DBP may have different allele
frequencies in different ethnic groups, the computer
program Eigensoft (v4.2) [14] was applied to estimate popu-
lation structure for the GWAS individuals. The Tracy-
Widom statistic was used to evaluate the statistical signifi-
cance of each principal component. The eigenvectors
corresponding to the statistically significant eigenvalues
were retrieved and used as covariates in the multiple re-
gression model mentioned under “Data Description” above.
Identity-by-descent mapping
Beagle Refined IBD (v4.0.r1128) was used to estimate
IBD sharing at each location on chromosome 3 [6]. The
parameter, ibdlength (the minimum IBD length to be
detected), was set to 1 cM. Other parameters, window
(the sliding window that determines the memory usage),
overlap (overlap between sliding windows), ibdtrim (end
of a candidate IBD segment trimmed before likelihood
calculation), and ibdwindow (sliding window for IBD
sharing detection), were set to be the number of markers
in 12, 1.5, 0.15, and 0.2 cM, respectively. Default settings
were used for the remaining parameters. IBD sharing
estimation was run 3 times using different seeds. Results
from these 3 runs were combined using the ibdmerge.jar
utility program (see “Website resources” below).
The physical map was from build GRCh37 of the
Genome Reference Consortium 2009. The genetic map
was generated by Dr. Brian Browning based on the
International Haplotype Map Project (HapMap) Phase II
genetic map (see “Website resources” below). If a marker
was not in this map, its genetic location was interpolated
based on its physical location.
Test for the relationship between identity-by-descent
sharing and diastolic blood pressure
A Perl script was written to create a matrix with the
number of unrelated individual pairs × the total number
of markers on chromosome 3. The observations in the
matrix only had 2 values: 0 if no IBD sharing was
observed for pair i at marker j, and 1 if IBD sharing was
observed for pair i at marker j.
Following the IBD mapping methods proposed for
quantitative traits using sibpairs [15–17], we calculated
both the squared trait difference (D) and squared trait
sum (S) for the DBP residuals for each unrelated pair.
Then, for each marker in the matrix, 2 simple linear
regressions were performed:
Table 1 Characteristics of the 105 unrelated individuals
Variable Category Frequency (%) or
Mean (SD, range)
Gender Male 43 (41 %)
Treatment Yes 22 (21 %)
Smoking status Yes 25 (24 %)
Age (years) 56.6 (15.5, 20.3–91.3)
Original DBP (mm Hg) 71.8 (9.3, 51–101)
Adjusted DBP (mm Hg) 72.9 (10.3, 51–101)
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Regression 2: YS on π with estimated slope β^S and
variance σS
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where π^ i is the observed IBD sharing (0 for no sharing
or 1 for sharing) for pair i.
Linkage was tested using a one-sided t test of the slope
estimate. Under the null hypothesis of no linkage, the
slope was zero whereas under the alternative hypothesis,
the locus was linked to the trait and the slope was nega-
tive. The t statistic was calculated as the weighted overall




Because the pairs of individuals were not independent
from each other, the significance threshold for the real
data was obtained using a permutation procedure.
Whole genome sequence data
For the chromosomal region with the most significant
relationship between IBD sharing and DBP, the sequence
data were examined to identify the risk variants for DBP.
First, variants with no variation (MAF = 0), more than 2
alleles, or a missing rate of more than 15 % were excluded.
The remaining genetic variants were annotated with the
Combined Annotation-Dependent Depletion (CADD)
scaled scores [18]. As recommended by the authors, a
genetic variant with a scaled score higher than 20 was
regarded as deleterious. The relationships between the
deleterious variants and DBP were analyzed using the
optimal sequence kernel association test (SKAT-O [19])
with gender, age, smoking status, and the first 3 principal
components as covariates.
Results
After the quality control procedures, 914 individuals and
374,179 markers were selected for relationship and
population structure analyses; and 105 unrelated Mexican
Americans and 52,216 markers from chromosome 3 of
the GWAS data were selected for IBD mapping (Table 1).
Three principal components were determined to besignificant for population structure and were used as
covariates in the multiple linear regression model for
DBP. None of the covariates was significantly associated
with DBP (ie, with p < 0.05); however, the first principal
component had a p value of 0.1 (ie, the DBP increased
18.2 mmHg for each unit increase in the first principal
component).
For the 105 unrelated individuals, there were 5460 pairs;
1573 (28.8 %) of them had detectable chromosomal
segments shared by IBD. The average length of the IBD
sharing segments was 1.47 cM with a range of 1.00 to
6.28 cM. The average chromosome-wide IBD sharing rate
was 0.0029 with a standard deviation of 0.0025 and a
range of 0 to 0.019. For each region, the rate was calcu-
lated with the number of pairs with IBD sharing at this
region divided by the total number of pairs (ie, 5460).
For the IBD mapping of DBP, the most significant
chromosomal region was at 3q12.3 with the peak single-
nucleotide polymorphisms (SNPs) located at 101,901,465
to 102,620,049 bp, a region bounded by the GWAS
markers that had IBD mapping p values of less than 0.01
(Fig. 1). The most significant p value for these markers
was 0.0016, which did not reach the estimated
chromosome-wide significance level 0.00012. For the
most significant region, the IBD sharing rate was 0.0057,
which was among the top 8 % of the rates for all the
regions on chromosome 3.
Of the 105 unrelated individuals, 71 had the whole-
genome sequence data. The most significant region
overlapped with 1 gene, the zona pellucida–like domain
containing 1 gene (ZPLD1), which is located at
101,818,088 to 102,196,462 bp. There were 3811 variants
at the region after the quality control procedures, 24 of
which were identified as deleterious (2 within the gene
ZPLD1). Based on the result from SKAT-O, these vari-
ants were not associated with DBP (p = 0.40).Discussion
We applied a population-based IBD mapping method to
a quantitative trait, DBP. Because of the relatively small
sample size (n = 105), statistical power to detect the
causal chromosomal region was low, and the most
Fig. 1 The IBD mapping results for (a) chromosome 3 and (b) the
3q12.3 to q13.11 region
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mated significance level.
Interestingly, however, the gene at the most significant
IBD mapping region, ZPLD1, has been reported to be
related to cerebral cavernous malformations, a disease
with enlarged small blood vessels (capillaries) in the
brain, in a patient with a balanced translocation [20].
From Genetic Analysis Workshop 18, Bonner et al. [21]
also reported an association between a sparse principal
component (which included 28 SNPs at the intergenic
region between ZPLD1 and MIR548A3) and systolic
blood pressure (SBP) using unrelated individuals from
the family data (n = 122) and the GWAS genotypes. The
Spearman correlation coefficient between the DBP and
SBP residuals was 0.59 (p <0.0001) in our data. Unfortu-
nately, we were not able to identify causal variants in
this gene for DBP. Further study with a large sample size
is needed to assess this result.
Using the same IBD sharing estimate method, Brown-
ing et al. [6] reported that the average genome-wide IBD
sharing rates were 0.015 for a Northern Finland sample
and 0.0041 for a United Kingdom (UK) sample [6]. Theaverage chromosome-wide rate was 0.0029 from our
Mexican American sample, which was lower than the
UK sample, as expected. A higher IBD sharing rate (ie,
on average, a larger combined length of detected IBD
sharing segments per pair of individuals) can be
obtained from an isolated founder population, such as
the Northern Finland sample. Current IBD mapping
methods are well powered to detect long IBD sharing
segments (>1 cM). However, as marker density increases
(eg, with whole genome sequencing data), IBD mapping
methods will be able to identify IBD sharing status for
small segments from outbred populations.
Conclusions
In summary, we demonstrated a gene mapping strategy
for quantitative traits which combines a population-
based IBD mapping method with sequence data ana-
lyses. However, as a result of the small sample size in
this study, more information about this approach and its
ability to prioritize causal variants for sequence data
analyses should be further explored.
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